Synopsis
Assess immune state, exposure history and treatment timing to deliver current indicated non-live vaccines, avoid unsafe live vaccines and create a specialist, documented protection plan.
- Do not use “immunocompromised” as one category: define disease, treatment, dose, duration, timing, transplant status, immune recovery and previous vaccine response.
- Inactivated and non-live vaccines cannot replicate and are generally safe, but immune response may be reduced and extra doses or timing changes may be recommended.
- Live attenuated vaccines can cause vaccine-strain disease in severe immunosuppression and are usually contraindicated unless an authoritative specialist pathway explicitly permits them.
Key red flags
Severe immunosuppression can permit uncontrolled vaccine-organism replication; identify vaccine platform rather than relying on brand familiarity.
Reasoning priorities
Record disease, therapy, dose, combination, last and next treatment, transplant stage and relevant immune recovery.
Map these facts to current Green Book definitions and specialist advice; a generic immunosuppressed label cannot determine safety.
Worked reasoning
A 48-year-old with rheumatoid arthritis is due first MabThera (rituximab) in eight weeks. Specialist pre-treatment assessment has confirmed that the severe-immunosuppression pneumococcal schedule applies. Records show no previous adult pneumococcal vaccination, no active infection and no relevant vaccine allergy; the planned treatment date is clinically acceptable.
- Confirm the specialist risk classification, treatment date and complete vaccination history. The severe-immunosuppression input is supplied for this case; do not assume every person with rheumatoid arthritis or every biologic prescription automatically has the same schedule.
- Choose PCV20, a non-live conjugate vaccine. Current UKHSA guidance requires two doses at least 4 weeks apart for this severe-immunosuppression group. MabThera product information for rheumatoid arthritis requires vaccination to be completed at least 4 weeks before the first infusion; the general 2-week preference does not replace that agent-specific interval.
- Through the authorised service, give PCV20 0.5 mL intramuscularly in the deltoid now, after consent and product checks, and book the second 0.5 mL dose for week 4. This leaves 4 further weeks before planned rituximab at week 8. The two-dose course follows national risk-group guidance. If dates change, obtain a specialist revised plan rather than compressing intervals or independently delaying urgent treatment.
- Document product, batch, date, route and administration of each dose; verify actual course completion and the final 4-week interval with the treatment team. Review other vaccine gaps separately and give an owned follow-up plan, recognising that vaccination does not guarantee adequate protection during B-cell depletion.